JP5024704B2 - A system that predicts the time required to treat a specific disease - Google Patents
A system that predicts the time required to treat a specific disease Download PDFInfo
- Publication number
- JP5024704B2 JP5024704B2 JP2007226494A JP2007226494A JP5024704B2 JP 5024704 B2 JP5024704 B2 JP 5024704B2 JP 2007226494 A JP2007226494 A JP 2007226494A JP 2007226494 A JP2007226494 A JP 2007226494A JP 5024704 B2 JP5024704 B2 JP 5024704B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- symptom
- evaluation function
- specific disease
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Measuring And Recording Apparatus For Diagnosis (AREA)
Description
本発明は、特定疾患の治療に要する期間を予測とその管理するシステムに関する。 The present invention relates to a system for predicting and managing a period required for treatment of a specific disease.
近年医療の分野では、アレルギー(Th2)マーチに基づいたテーラーメイド療法による疾患への早期介入(二次的巡行疾患の治療)が実践されている。また、医療の均一を、臨床的アウトカムを目指したクリニカルパスによって、医療チームよる治療と管理の有効性が強調されている。クリニカルパスとは、ある種の疾患をもつ患者個体に対する医療チーム(患者本人を含む)による治療・検査・ケア・処置・指導などの内容やタイミング、患者の状態などを時間軸に沿ってまとめた工程管理表に相当するものである。 In recent years, early intervention for diseases (treatment of secondary circulatory diseases) by tailor-made therapy based on allergy (Th2) march has been practiced in the medical field. In addition, the clinical path aiming at clinical outcomes for medical uniformity emphasizes the effectiveness of treatment and management by medical teams. The clinical path is a summary of the contents and timing of treatment, examination, care, treatment, guidance, etc. by the medical team (including the patient) for individual patients with certain diseases along the time axis. This corresponds to a process management table.
近年の医療機関はこの疾患毎にクリニカルパスを作成し、クリニカルパスリスト(チェック表)に基づいて患者のトータルケアを行っている。 Medical institutions in recent years create a clinical path for each disease, and perform total patient care based on a clinical path list (check table).
新規に開発(発見)したTh疾患マーチ(多くの疾患は発症する時期とその疾患とに規律があって、一見関係のない疾患も巡行(march)する。このことを明らかにしたので二次的にマーチングする疾患の早期介入(治療)が可能となる方法(例:Th1あるいはTh1疾患のリウマチ→Th2にシフト(アレルギーの発生をみる)を実施したn=2)を具現化した。 Newly developed (discovered) Th disease march (Many diseases are disciplined in the time of onset and the disease, and seemingly unrelated diseases are marched. A method that enables early intervention (treatment) of diseases that are marching (eg, rheumatoid arthritis in Th1 or Th1 disease to Th2 (see the occurrence of allergies) n = 2) was realized.
この方法をアウトカムにしたクリニカルパスを作成する上で、治療に要する期間を見積もることが必要(当該疾患群を同一化して比較するために日数に変換)であるが、疾患によっては、治療に要した期間が大きくばらつき、患者に確かな治療期間あるいは治癒に要する日数を伝えることができないという問題があった。例えば、アトピー性皮膚炎(Th2優位疾患)などは固体差や治療方法によってその治療期間が大きくばらつき、また予測をしたテーラーメイド療法の日数を伝えることはできない。 In creating a clinical path with this method as an outcome, it is necessary to estimate the time required for treatment (converted to days for the same disease group to be identified and compared), but depending on the disease, treatment may be necessary. There was a problem that the period of treatment was greatly varied and the patient could not be told of a certain treatment period or the number of days required for healing. For example, the duration of treatment for atopic dermatitis (Th2-dominant disease) varies greatly depending on individual differences and treatment methods, and the predicted number of days of tailor-made therapy cannot be conveyed.
そこで、本発明は、特定疾患の外観的形態から、二次的にマーチする特定疾患に対する確かな治療期間を算出することができるシステムとTh生体反応検査によるテーラーメイド医療の施術期間を提供することを目的とする。 Therefore, the present invention provides a system capable of calculating a reliable treatment period for a specific disease that is secondarily marched from the appearance form of the specific disease, and a treatment period for tailor-made medical treatment based on a Th biological reaction test. Objective.
前記目的を達成するために、本発明は特定疾患の外観的形態に関するユーザからの入力に基づいて、前記特定疾患の治療に要する期間を予測するシステムと刻一刻と変化する症状の推定治療必要日数とを予測するシステムにおいて、前記両システムは、記憶手段と処理手段とを備え、前記処理手段は、前記外観的形態に関係する複数の症状項目の各症状項目について、テーラーメイド療法による症状の程度に応じて複数の選択肢をユーザに提供し、当該ユーザが前記複数の選択肢の少なくとも一つを選択できるようにする手段を備え、前記記憶手段は、前記予測に用いられる評価関数であって、複数の実モデルついて、前記複数の症状項目の各症状項目と治療期間の実測値とについて因子分析を行って、前記複数の各症状項目の前記治療期間に与える重み付け係数を求め、前記各症状項目に前記重み付け係数を適用したものを合計してなる前記評価関数と、前記ユーザによって選択された選択肢に対するスコアと、を記録しており、前記処理手段は、さらに、前記評価関数と前記スコアとを前記記憶手段から読み出し、前記読み出したスコアを前記読み出した評価関数の該当する前記症状項目に代入して治療期間を算出する手段を備える、ことを特徴とするものである。 In order to achieve the above object, the present invention provides a system for predicting the time required for the treatment of the specific disease based on the input from the user regarding the external form of the specific disease, and the estimated number of days required for treatment of the symptom changing every moment. The both systems include storage means and processing means, and the processing means has a degree of symptoms by tailor-made therapy for each symptom item of a plurality of symptom items related to the appearance form. And a means for providing a plurality of options to a user in response to the user, and the user can select at least one of the plurality of options, and the storage means is an evaluation function used for the prediction, For the actual model, the factor analysis is performed on each symptom item of the plurality of symptom items and the actual measurement value of the treatment period, and the treatment period of the plurality of symptom items The weighting coefficient to be given is obtained, and the evaluation function formed by adding the weighting coefficient applied to each symptom item and the score for the option selected by the user are recorded, and the processing means includes: Furthermore, the evaluation function and the score are read out from the storage means, and a means for calculating a treatment period by substituting the read score into the corresponding symptom item of the read evaluation function is provided. Is.
また、クリニカルパスを医療チームとして共有できることを特徴とするインターネット軽量化医療システムである。 In addition, the Internet light weight medical system is characterized in that the clinical path can be shared as a medical team.
本発明によれば、特定疾患の外観的形態から、この特定疾患に対する確かな治療期間を算出することと、Th疾患としてマーチングする二次疾患の早期介入ができるシステムを提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the system which can calculate the reliable treatment period with respect to this specific disease from the external form of a specific disease, and the early intervention of the secondary disease marching as Th disease can be provided.
次に本発明の実施形態について説明する。図1は、特定疾患の治療に要する期間を予測するシステムを実現するためのコンピュータシステムである。このコンピュータシステムは、入力装置と、メモリと、演算処理ユニットと、表示デバイスと、を備えて構成されている。 Next, an embodiment of the present invention will be described. FIG. 1 is a computer system for realizing a system for predicting a period required for treatment of a specific disease. This computer system includes an input device, a memory, an arithmetic processing unit, and a display device.
次に、このコンピュータシステムの動作を、リウマチ(Th1)に二次的マーチング疾患である犬のアトピー性皮膚炎の治療に要する期間を予測することを例にして説明する。発明者は、犬のアトピー性皮膚炎の外観的症状を次の各症状項目から評価した。 Next, the operation of this computer system will be described by taking as an example the prediction of the period required for the treatment of atopic dermatitis in a dog, which is a secondary marching disease, in rheumatism (Th1). The inventor evaluated the appearance symptoms of atopic dermatitis in dogs from the following symptom items.
深さ、滲出液、皮膚患部の大きさ、炎症と感染の評価(合併症)、肉芽組織、壊死組織、皮膚ポケットの存在(薬疹:アナジー)。 Depth, exudate, size of affected skin, evaluation of inflammation and infection (complications), granulation tissue, necrotic tissue, presence of skin pocket (drug eruption: anergy).
さらに、発明者は各項目について、次の通り複数の選択肢を設定した。
〔深さ〕
○皮膚異常も発赤もない状態
○持続する発赤の状態
○皮膚表面から真皮まで
○皮下組織までに及ぶ
○皮膚が完全に断裂
○皮膚が断裂しているが深さが判定できない
〔滲出液〕
○滲出液はない
○少量(ガーゼが滲出液で少し濡れる程度)
○中等量(1日1回ガーゼを交換する程度)
○多量(1日2回以上交換する程度)
〔炎症と感染の評価〕
○合併症が存在するが局所の炎症兆候がみられないもの
○患部に炎症兆候が見られるもの(発赤、ブドウ球菌感染症など)
○患部に明らかな感染兆候が見られるもの(ブドウ球菌感染症、マラセチア感染症などを含む)
○全身的影響が見られるもの(合併症の存在が確実な上に皮膚の発赤などを伴う)
〔肉芽組織〕
○既に治癒したか、または肉芽形成の評価ができない
○良性肉芽が90%以上を占める
○良性肉芽が50%〜90%を占める
○良性肉芽が10%〜50%を占める
○良性肉芽が10%未満
○良性肉芽が全く無い
〔壊死組織〕
○壊死組織は見られない
○柔らかい壊死組織がある
○硬く厚く密着した壊死組織がある
〔皮膚ポケットの存在〕
○ポケットなし
○4未満
○4〜16未満
○16〜36未満
○36以上
発明者は各症状項目の各選択肢とアトピー性皮膚炎の治療まで要した実例(500例)について因子分析を行い、治療期間に与える各症状項目の重み付け(重相関係数の固有値)を求め、治療期間を予測する評価関数を得た。評価関数(疾患の根本原因に対する因子係数)は次のとおりである。
Furthermore, the inventor set a plurality of options for each item as follows.
〔depth〕
○ State without skin abnormalities or redness ○ Persistent redness state ○ From the skin surface to the dermis ○ Extends to the subcutaneous tissue ○ The skin is completely ruptured ○ The skin is torn but the depth cannot be determined [exudate]
○ There is no exudate ○ Small amount (the gauze gets slightly wet with the exudate)
○ Medium equivalent (exchanging gauze once a day)
○ Large amount (exchanging at least twice a day)
[Evaluation of inflammation and infection]
○ Those with complications but no local signs of inflammation ○ Those with signs of inflammation in the affected area (redness, staphylococcal infection, etc.)
○ Those with obvious signs of infection (including staphylococcal infections, malassezia infections, etc.)
○ Those that have systemic effects (with certainty of complications and skin redness)
[Granulation tissue]
○ Already healed or unable to evaluate granulation formation ○ Benign granulation accounts for 90% or more ○ Benign granulation accounts for 50% to 90% ○ Benign granulation accounts for 10% to 50% ○ Benign granulation 10% Less than ○ no benign granulation
[Necrotic tissue]
○ Necrotic tissue is not seen ○ Soft necrotic tissue is present ○ Hard and thick necrotic tissue is present
[Presence of skin pocket]
○ No pocket ○ Less than 4 ○ Less than 4-16 ○ Less than 16-36 ○ More than 36
The inventor performs a factor analysis on each example of each symptom item and an example (500 cases) required for the treatment of atopic dermatitis, and obtains a weight (eigenvalue of the multiple correlation coefficient) of each symptom item given to the treatment period, An evaluation function to predict the treatment period was obtained. The evaluation function (factor coefficient for the root cause of the disease) is as follows.
アトピー性皮膚炎の皮膚の推定治療日数(days)=
((0.875*1.5)ד深さ” )+(((1.028*1.5)ד滲出液”) - 1.4)+(((1.175*1.5)ד皮膚病変の大きさ”) -4)+(((1.571*1.5)ד合併症”)-16)
各症状項目に対応する数値は重み付けの結果得られた特性値である。“ ”内の各症状項目には、ユーザによって選択された選択肢に対応するスコアが代入される。但し、“皮膚病変の大きさ”には皮膚病変の面積(平方cm)が代入される。
Estimated days of treatment for atopic dermatitis skin (days) =
((0.875 * 1.5) x "depth") + (((1.028 * 1.5) x "exudate")-1.4) + (((1.175 * 1.5) x "size of skin lesion") -4) + (((1.571 * 1.5) x "complication")-16)
The numerical value corresponding to each symptom item is a characteristic value obtained as a result of weighting. For each symptom item in “”, a score corresponding to the option selected by the user is substituted. However, the area (square cm) of the skin lesion is substituted for “the size of the skin lesion”.
前記評価関数メモリに予め記録されている。前記症状項目毎に前記選択肢を表示するためのプログラム及びデータが予めメモリに記録されている。各選択肢に対するスコアが予めメモリに記録されている。 It is recorded in advance in the evaluation function memory. A program and data for displaying the options for each symptom item are recorded in the memory in advance. A score for each option is recorded in the memory in advance.
次に図1に示すシステムの動作について説明する。ユーザがシステムを起動すると、処理装置は表示デバイスに既述の症状項目と既述の選択肢を表示デバイスに表示する。 Next, the operation of the system shown in FIG. 1 will be described. When the user activates the system, the processing apparatus displays the above described symptom items and the above described options on the display device.
次いでユーザが犬の皮膚形態を観察して、入力装置を利用して症状項目毎に該当する選択肢を選択する。“皮膚病変の大きさ”には皮膚病変の面積(平方cm)を入力する。 Next, the user observes the skin shape of the dog and selects an appropriate option for each symptom item using the input device. In the “skin lesion size”, the area (square cm) of the skin lesion is input.
また、根本原因(Th2反応優位=衛生仮説)は別途に要治療日数を計量化する因子があり、実際には上記日数に根本日数を加算して評価するコンピュータシステムである。同様にしてすべてのTh疾患を日数化して使用可能であるシステムステムの体裁としてインターネットに構築した。 In addition, the root cause (Th2 reaction superiority = hygiene hypothesis) is a factor that separately measures the number of days requiring treatment, and is actually a computer system that evaluates by adding the number of days to the above days. Similarly, it was constructed on the Internet as an appearance of a system stem that can be used by converting all Th diseases into days.
処理ユニットは、ユーザから入力がある都度入力結果をメモリに記録する。ユーザの入力が終了すると、処理ユニットはメモリから既述の評価関数と入力結果である既述のスコアと皮膚病変の面積を読み出し、入力結果を評価関数に代入して、アトピー性皮膚炎の皮膚の推定治療日数(days)を求め、推定治療日数を表示デバイスに表示する。根本原因であるTh2の変化をも評価可能である。 The processing unit records the input result in the memory every time there is an input from the user. When the user's input is completed, the processing unit reads the above-described evaluation function, the above-described score, which is the input result, and the area of the skin lesion from the memory, substitutes the input result into the evaluation function, and the skin of atopic dermatitis The estimated treatment days (days) are obtained, and the estimated treatment days are displayed on the display device. The change of Th2 that is the root cause can also be evaluated.
発明者が鋭意検討したところ、アトピー性皮膚炎はTh2反応(真の病因)がTh1反応に対して優位であることによって発症する。そこで、Th1反応値に対するTh2反応値の比を既述の評価関数に外挿することによって、アトピー性皮膚炎の根本原因を含めて推定治療日数を求めることができる。またこのことにより推定した日に完治させることも可能である。 As a result of intensive studies by the inventor, atopic dermatitis develops because the Th2 response (true pathogenesis) is superior to the Th1 response. Therefore, by extrapolating the ratio of the Th2 response value to the Th1 response value to the above-described evaluation function, the estimated number of treatment days including the root cause of atopic dermatitis can be obtained. In addition, it is possible to cure completely on the estimated day.
なお、Th1反応とは、リンパ球等の細胞が異物を攻撃する細胞性免疫反応であり、Th1細胞から産生され、免疫細胞の機能を調節する蛋白質(サイトカイン)のひとつであるインターフェロンγの産生を特徴とする。同じくサイトカインのひとつであるインターロイキン4の産生を特徴とするTh2反応とは排他的に作用する。 The Th1 reaction is a cell-mediated immune reaction in which cells such as lymphocytes attack foreign substances, and the production of interferon γ, one of the proteins (cytokines) that are produced from Th1 cells and regulate the function of immune cells. Features. It acts exclusively with the Th2 reaction, which is also characterized by the production of interleukin 4, which is also a cytokine.
既述の実施形態では、犬のアトピー性皮膚炎に対する治療日数を予測するシステムについて説明したが、これに限られること無く本発明が有効なかぎりいかなる疾患モデルについても治療日数を推定することができる。 In the above-described embodiment, a system for predicting the number of treatment days for atopic dermatitis in dogs has been described. However, the present invention is not limited thereto, and the number of treatment days can be estimated for any disease model as long as the present invention is effective. .
Claims (1)
前記システムは、記憶手段と処理手段とを備え、
前記処理手段は、前記外観的形態に関係する複数の症状項目の各症状項目について、症状の程度に応じて複数の選択肢をユーザに提供し、当該ユーザが前記複数の選択肢の少なくとも一つを選択できるようにする手段を備え、
前記記憶手段は、前記予測に用いられる評価関数であって、複数の実モデルついて、前記複数の症状項目の各症状項目と治療期間の実測値とについて因子分析を行って、前記複数の各症状項目の前記治療期間に与える重み付け係数を求め、前記各症状項目に前記重み付け係数を適用したものを合計してなる前記評価関数と、前記ユーザによって選択された選択肢に対するスコアと、を記録しており、
前記処理手段は、さらに、前記評価関数と前記スコアとを前記記憶手段から読み出し、前記読み出したスコアを前記読み出した評価関数の該当する前記症状項目に代入して治療期間を算出する手段を備える、
特定疾患の治療に要する期間を予測するシステム。 In a system for predicting a period required for treatment of a specific disease based on an input from a user regarding an external form of the specific disease,
The system comprises storage means and processing means,
The processing means provides a user with a plurality of options for each symptom item of the plurality of symptom items related to the appearance form, and the user selects at least one of the plurality of options. With the means to be able to
The storage means is an evaluation function used for the prediction, and performs a factor analysis on each symptom item of the plurality of symptom items and an actual measurement value of a treatment period for a plurality of real models, and The weighting coefficient given to the treatment period of the item is obtained, and the evaluation function formed by adding the weighting coefficient applied to each symptom item and the score for the option selected by the user are recorded. ,
The processing means further comprises means for reading the evaluation function and the score from the storage means, and calculating a treatment period by substituting the read score into the corresponding symptom item of the read evaluation function,
A system that predicts the time required to treat a specific disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007226494A JP5024704B2 (en) | 2007-08-31 | 2007-08-31 | A system that predicts the time required to treat a specific disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007226494A JP5024704B2 (en) | 2007-08-31 | 2007-08-31 | A system that predicts the time required to treat a specific disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009056133A JP2009056133A (en) | 2009-03-19 |
| JP5024704B2 true JP5024704B2 (en) | 2012-09-12 |
Family
ID=40552436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007226494A Expired - Fee Related JP5024704B2 (en) | 2007-08-31 | 2007-08-31 | A system that predicts the time required to treat a specific disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5024704B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7304203B2 (en) | 2019-05-14 | 2023-07-06 | キヤノンメディカルシステムズ株式会社 | Medical information processing device and program |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002288340A (en) * | 2001-03-27 | 2002-10-04 | Takayoshi Yamamoto | Diagnosing method by oriental medicine and computer for performing diagnosing method |
| JP2002351977A (en) * | 2001-05-28 | 2002-12-06 | Sanyo Electric Co Ltd | Apparatus and method for providing therapeutic information |
| JP4393081B2 (en) * | 2003-02-26 | 2010-01-06 | 株式会社東芝 | Virtual patient system |
| JP3871144B1 (en) * | 2005-11-15 | 2007-01-24 | 国立大学法人岐阜大学 | Diagnosis support device |
-
2007
- 2007-08-31 JP JP2007226494A patent/JP5024704B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009056133A (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robson et al. | Wound healing trajectories as predictors of effectiveness of therapeutic agents | |
| Kornman et al. | Quo vadis: what is the future of periodontics? How will we get there? | |
| Gralnek et al. | Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials | |
| Parker | Decision-making models used by medical-surgical nurses to activate rapid response teams. | |
| JP2017518283A5 (en) | ||
| Conway et al. | Implementing a thermal care bundle for inadvertent perioperative hypothermia: A cost-effectiveness analysis | |
| Nguyen et al. | Cost-effectiveness of indocyanine green angiography in postmastectomy breast reconstruction | |
| Ortendahl et al. | The methotrexate therapeutic response in rheumatoid arthritis. | |
| Raza et al. | Supervised autoregressive exogenous networks with fractional Grünwald–Letnikov finite differences: Tumor evolution and immune responses under therapeutic influence fractals model | |
| JP5024704B2 (en) | A system that predicts the time required to treat a specific disease | |
| Alici et al. | Brucella infective endocarditis | |
| Hollestein et al. | Missing data in clinical research: an integrated approach. | |
| Manukova-Marinova et al. | Algorithm and Software System for Treatment Application of Platelet-Rich Plasma on Problematic Skin Wounds | |
| Rudnicka et al. | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect | |
| Burns et al. | Skincare bundle for the very low birth weight and extremely low birth weight neonate | |
| Boet et al. | Protocol for a multicentre randomized controlled trial of normobaric versus hyperbaric oxygen therapy for hypoxemic COVID-19 patients | |
| Herzke et al. | Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss | |
| Flores-Garza et al. | Mathematical model of the immunopathological progression of tuberculosis | |
| Siracuse et al. | Readmissions after firearm injury requiring vascular repair | |
| Gbegnon et al. | Machine learning algorithm for accurate, automated, real-time prediction of surgical site infections using EHR data | |
| Marcus et al. | Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation | |
| Sheng et al. | 873: Pre-selected oxycodone in a post-vaginal delivery order set does not affect discharge opioid prescriptions | |
| Deborde et al. | [OP. 2A. 07] TRENDS IN PATIENTS ATTENDING A TERTIARY HYPERTENSION UNIT: PATIENTS’CHARACTERISTICS AND TREATMENT STRATEGIES STRONGLY EVOLVED OVER THE LAST 15 YEARS | |
| Ackerman | Finding More Information on Pet-Specific Care Topics | |
| Krishna Trivedi et al. | Assessing the Significance of Hyperthermia in Newborns Undergoing Phototherapy for Hyperbilirubinemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100709 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120524 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120531 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120608 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5024704 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |